Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy

Phase 3

Conditions: Pneumonia, Viral
Coagulation Disorder
COVID

Interventions: Drug: Enoxaparin

First Posted Date: 2020-05-29

Last Posted Date: 2020-05-29

Lead Sponsor: Azienda Ospedaliero-Universitaria di Modena

Target Recruit Count: 300

Registration Number: NCT04408235

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria, Modena, Italy

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Phase 4

Terminated

Conditions: COVID-19

Interventions: Drug: Enoxaparin sodium
Drug: Unfractionated heparin
Drug: Fondapariniux
Drug: Argatroban

First Posted Date: 2020-05-28

Last Posted Date: 2023-09-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 14

Registration Number: NCT04406389

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States

Pharmacodynamic Equivalence of Ovine Enoxaparin to Lovenox®

Phase 1

Completed

Conditions: Enoxaparin

Interventions: Drug: Ovine Enoxaparin
Drug: Enoxaparin Prefilled Syringe [Lovenox]

First Posted Date: 2020-05-27

Last Posted Date: 2020-05-27

Lead Sponsor: Indonesia University

Target Recruit Count: 20

Registration Number: NCT04402762

Locations: 🇮🇩
Pharma Metric Labs, Jakarta Pusat, Jakarta, Indonesia

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Phase 3

Completed

Conditions: Sars-CoV2
COVID

Interventions: Drug: Enoxaparin
Drug: Prophylactic/Intermediate Dose Enoxaparin

First Posted Date: 2020-05-26

Last Posted Date: 2021-11-22

Lead Sponsor: Northwell Health

Target Recruit Count: 257

Registration Number: NCT04401293

Locations: 🇺🇸
Lenox Hill Hospital, New York, New York, United States
🇺🇸
Beth Israel Newark, Newark, New Jersey, United States
🇺🇸
Staten Island University Hospital, Staten Island, New York, United States

and more 3 locations

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Phase 3

Terminated

Conditions: Pulmonary Embolism, Deep Vein Thrombosis
COVID-19

Interventions: Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml

First Posted Date: 2020-05-26

Last Posted Date: 2022-05-25

Lead Sponsor: University of Zurich

Target Recruit Count: 475

Registration Number: NCT04400799

Locations: 🇨🇭
University Hospital Bern, Bern, Switzerland
🇨🇭
Hôpitaux Universitaires Genève, Geneva, Switzerland
🇨🇭
Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

and more 5 locations

Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial

Phase 4

Completed

Conditions: Coronavirus Infection

First Posted Date: 2020-05-19

Last Posted Date: 2021-06-10

Lead Sponsor: Brazilian Clinical Research Institute

Target Recruit Count: 615

Registration Number: NCT04394377

Locations: 🇧🇷
Centro de Pesquisa Clínica do Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil
🇧🇷
Núcleo de Ciências de Saúde - Unidade de Pesquisa - Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil
🇧🇷
Centro de Estudos Clínicos do Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil

and more 33 locations